At present, we manufacture over 50 prescription medicines in 5 core therapeutic areas, including liver diseases, oncology, respiratory diseases, antibiotics and diabetes.

CTTQ maintains high annual revenue growth in recent years, and its total sales reached 18.07 billion RMB in 2020. Our APIs and FDFs are sold to all major continents including Americas, Europe, Asia, and Africa.

CTTQ has 2 R&D centers institutes with a total of over 1800 employees. We invest 10%-12% of our annual sales revenue in R&D every year. There are more than 190 projects in our product pipeline, in which State CategoryⅠinnovative drug projects make up more than 40%.

CTTQ pays special attention to intellectual property and patent protection. By the end of 2020, we have filed 1679 patents, including 1564 inventions. Among them, 586 patents have been granted, including 507 inventions.

We currently have 3 manufacturing plants focusing on FDF and API production, 2 R&D centers, 1 overseas branch (CTTQ EU) in Barcelona, Spain, 1 business development office in San Diego, USA, and 4 joint labs (in Shanghai and Chengdu).

We have 4 solid dosage form and injectable products passed US and EU inspection. CTTQ is the first company that obtained the new version of the Chinese GMP certificate. Our customer base spans over 30 countries.

The Fulvestrant Injection and Fosaprepitant Dimeglumine for Injection developed by CTTQ has been dispatched to EU and US market. Another co-developed innovative drug, Anlotinib, was designated Orphan Drug status for treatment of ovarian cancer by FDA. Its multiple clinical trials are ongoing for other indications.

We are looking forward to establishing solid collaborations with partners around the world.